3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pain
19
Neoplasms
17
Cancer Pain
15
Pain, Postoperative
12
Agnosia
8
Chronic Pain
7
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Breast Neoplasms
4
Multiple Myeloma
3
Mucositis
3
Lymphoma, Follicular
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia, Biphenotypic, Acute
3
Leukemia
3
Wounds and Injuries
2
Waldenstrom Macroglobulinemia
2
Thrombocythemia, Essential
2
Supratentorial Neoplasms
2
Sezary Syndrome
2
Primary Myelofibrosis
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Precancerous Conditions
2
Polycythemia Vera
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Pancreatic Neoplasms
2
Interventions
Morphine
1
Ketamine
1
Chitosan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cancer: Breakthrough Pain
×
Morphine
×
Clear all
NCT02591017
2018-11-13
ONKEMI
University Hospital, Basel, Switzerland
Phase 3
Terminated
11 enrolled